Quality of Life and Symptomatic Response in Myelofibrosis Patients Receiving an Allogeneic Stem Cell Transplant


About this study

The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • All patients must have myelofibrosis (MF) including primary MF, Post-ET, or Post–PV MF.
  • Patients must be planning to undergo allogeneic HSCT (matched or mismatched  related/matched or mismatched unrelated with HLA typing completed during initial stem cell transplant evaluation).
  • Participants must be willing to complete a packet of metrics (MPN-SAF and FACT-BMT) at the pre-transplant evaluation (within one month of start of conditioning), day 30, day 100 and 1 year post-transplant and sign informed consent (see attached)  prior to enrollment.  Metric packages will be available in English, Italian, Swedish, French, German, Dutch, and Spanish.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jeanne Palmer, M.D.

Open for enrollment

Contact information:

Regina Becker



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer